Specialities

Specialities

Respiratory Infections
Airway Diseases
Allergy
Asthma
Bronchiectasis
Bronchitis
Chronic Cough
COPD
COVID-19
Cystic Fibrosis
Idiopathic Pulmonary Fibrosis
Interstitial Lung Disease
Interventional Pulmonology
Lung Cancer
Paediatric Respiratory Medicine
Respiratory Tract Disorders
Pulmonary Embolism
Pulmonary Hypertension
Respiratory Intensive Care
Rhinosinusitis
Sleep Related Breathing Disorders
Thoracic Oncology
Lung Transplantation and Surgery
Ventilation
Lung Health
Rare Diseases
Search

Trending Topic
4 mins

Trending Topic
Developed by Touch
Mark CompleteCompleted
BookmarkBookmarked

Foreword – touchREVIEWS in Respiratory & Pulmonary Diseases, Volume 9, Issue 1, 2024

Welcome to the latest edition of touchREVIEWS in Respiratory & Pulmonary Diseases. As we continually strive to deliver cutting-edge research and insightful commentary, this issue is no exception, featuring a diverse array of articles that illuminate both emerging treatments and evolving practices within the field of respiratory and pulmonary medicine. We begin with a compelling […]

touchREVIEWS in Respiratory & Pulmonary Diseases. 2024;9(1):1-2

Connect With Us:

Facebook
X (Twitter)
Instagram
Youtube
Linkedin
Interstitial Lung Disease

Elisabeth Bendstrup, ERS 2021: Challenges and Advances in ILD

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Published Online: Sep 9th 2021

We were delighted to talk with Professor Elisabeth Bendstrup (Aarhus University Hospital, Denmark) around the barriers and latest advances in treating interstitial lung disease.

Questions

  1. What are the barriers to the early diagnosis of interstitial lung disease (ILD)? (0:18)
  2. What are the hot topics and latest research you are looking forward to exploring in ILD during 2021? (2:05)

Disclosures: Elisabeth Bendstrup has received grants or personal fees for talks, advisory board meetings, travel support for conferences and meetings from Boehringer Ingelheim, Roche, AStraZeneca, Galapagos, Bristol Myers Squibb in recent years.

Support: Interview and filming supported by Touch Medical Media. Interview conducted by Victoria Jones.

Filmed as a highlight of ERS 2021 (Virtual).

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied

Trending Topic
Developed by Touch
Mark CompleteCompleted
BookmarkBookmarked

Mirtazapine does not alleviate severe breathlessness: Insights from the BETTER-B study

Irene Higginson

The BETTER-B study, recently presented at ERS and published in The Lancet Respiratory Medicine, provided new insights into the management of severe breathlessness in patients with chronic respiratory diseases such as COPD and Interstitial Lung Disease (ILD).  Severe breathlessness is a debilitating symptom that significantly impacts the quality of life for millions of people worldwide, yet there are currently no licensed medications to effectively address it outside of Australia. Given the clinical challenges and limited treatment options, clinicians often resort to off-label use of medications like mirtazapine, a widely prescribed antidepressant that appeared promising. Despite its initial promise, the study found that doses ranging from 15 to 45 mg of mirtazapine failed to provide significant relief compared to a placebo. Additionally, the findings highlighted potential adverse effects and increased healthcare costs associated with its use. 

Advertisement

    • Related Videos in Interstitial Lung Disease

    Latest articles videos and clinical updates - straight to your inbox

    This Functionality is for
    Members Only

    Explore the latest in medical education and stay current in your field. Create a free account to track your learning.

    Close Popup